Prospector
Profile
07.1199
|
| |
| Fermavir Pharmaceuticals, Inc. |
NAICS |
541710 |
| 420 Lexington Avenue, Suite 445
New York, NY 10170 |
Description |
Biotechnology |
| (212) 413-0802 |
Employees |
1 |
| http://www.fermavir.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-12.3360 |
| |
Assets |
(mil) |
0.5850 |
| |
Liability |
(mil) |
1.0750 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
BDO Seidman LLP raised substantial doubt that Fermavir Pharmaceuticals, Inc. will be able to continue as a going concern after auditing its financial statements for the year ended April 30, 2007. The Company has incurred losses totaling $17,918,771 since inception and has negative working capital.
|
| |
|
Intellectual Property:
The Company currently has received two issued U.S. patents and nine non-U.S. patents describing compounds, compositions and methods for treating viral disease. The Company has two pending United States patent applications describing compounds, compositions and methods of treating and preventing viral disease. It also has filed related patent applications under the Patent Cooperation Treaty (PCT) as well as other non-United States national and/or regional patent applications. [SEC Filing 10-KSB 08-03-07]
|
| |
|
Description:
The Company holds licensed patents for a series of compounds for the treatment of viral diseases in the United States.
|
| |
|
Officers:
Gabriele M. Cerrone (Chair); Geoffrey W. Henson, Ph.D. (CEO & Dir.); Frederick Larcombe (CFO); Erik DeClercq, MD, Ph.D. (Dir.); Richard J. Whitley, MD (Dir.); Chris McGuigan, Ph.D. (Dir.); John P. Brancaccio (Dir.)
|
| |
|
Auditor:
BDO Seidman LLP
|
| |
|
Securities:
Common Stock-Symbol FMVR.OB; OTC BB;
20,853,231 common shares outstanding as of July 27, 2007.
|
| |
| |
| |
| return to main page |
